04 韩国疫苗接种工作开始发力

韩国卫生官员周四公布了向普通公众开放疫苗接种的计划，该国有望在9月底之前为四分之三人口接种疫苗。

全文共683个词，by Song Jung-a, Edward White, in Seoul

South Korea is on track to inoculate three-quarters of its 52m people against Covid-19 over the next three months as the vaccine rollouts of east Asian governments gather momentum after early delays.

韩国有望在9月底之前为四分之三人口（韩国总人口为5200万）接种新型冠状病毒肺炎（Covid-19，即2019冠状病毒病）疫苗。东亚各国政府的疫苗接种工作在最初的延迟后开始发力。

Health officials in Seoul unveiled plans on Thursday to expand its vaccination programme to the general public after inoculating 13m people, one-quarter of the population, two weeks ahead of schedule.

韩国卫生官员周四公布了向普通公众开放疫苗接种的计划，该国已比原计划提前两周为1300万人——韩国人口的四分之一——接种了疫苗。

The surge in vaccinations comes after Asian countries, which outperformed Europe and the US in their initial responses to the coronavirus pandemic, fell behind their western counterparts this year in securing and delivering jabs.

亚洲国家对新冠大流行的最初应对要好于欧洲和美国，但在这次大幅加快疫苗接种之前，它们今年在取得和为民众接种疫苗方面落后于西方国家。

East Asia’s struggles were attributed to a lack of local Covid vaccine manufacturers as well as inertia on the part of policymakers after their early success suppressing the virus.

东亚的困难一部分在于当地缺乏新冠疫苗制造商，还有一部分在于政策制定者在早期成功抑制疫情后的惰性。

A strong rebound in export growth and signs of inflationary pressures have masked weaker domestic recoveries across the region amid continued social distancing and restrictions on travel, tourism and mass events.

出口增长的强劲反弹和出现通胀压力的迹象，掩盖了在社交隔离措施继续实施以及人员出行、旅游和大型活动继续受到限制的情况下，该地区各国国内较弱的复苏。

Société Générale analysts described China’s lack of acceleration in domestic consumption in particular as “a big concern”，with the country’s retail and services sectors still underperforming and the export recovery set to moderate.

法国兴业银行(Société Générale)分析师称中国国内消费增长乏力是“一大问题”，中国的零售和服务业仍表现不佳，而且出口复苏即将降温。

Seoul is in talks with other governments about quickly loosening travel restrictions as the vaccination drive gathers pace.

随着疫苗接种行动的加快，韩国政府正在与别国政府商量尽快放松旅行限制。

“The slump in the service sector—travel, retail, restaurant and hotels—makes it difficult to create a positive cycle for the economy, despite strong exports,” said Park Chong-hoon, head of research at Standard Chartered in Seoul.

渣打银行(Standard Chartered)驻首尔研究主管Park Chong-hoon表示：“尽管出口强劲，但服务业——旅行、零售、餐饮和酒店——的低迷，使得经济难以进入良性循环。”

South Korea will also allow citizens to be vaccinated with different jabs as part of a plan to navigate supply shortages and reach its target of herd immunity by November. That means about 760,000 people, including healthcare workers who initially received the Oxford/AstraZeneca jabs, can receive their second dose with a BioNTech/Pfizer vaccine.

韩国还将允许公民接种不同种类的疫苗，从而帮助缓解供应短缺，以完成在11月前实现群体免疫的目标。这意味着大约76万人，包括最初接种了牛津/阿斯利康(Oxford/AstraZeneca)疫苗的医护人员，第二针可以接种BioNTech/辉瑞(Pfizer)疫苗。

“Things seem to be going as well as planned by the government, with little public resistance against vaccinations,” said Kim Tak, a professor of infectious disease at Soon Chun Hyang University Hospital.

“事情的进展似乎和政府计划的一样顺利，公众对接种疫苗几乎没有什么抵制。”顺天乡大学医院(Soon Chun Hyang University Hospital)传染病学教授Kim Tak说。

South Korea’s vaccination rate has outpaced that of neighbouring Japan despite Tokyo’s rush to inoculate citizens ahead of the Olympic Games in July. While both countries had barely started their campaigns in April, cumulative doses per 100 people in South Korea have jumped to more than 30 in recent days, compared with just over 20 in Japan.

韩国的疫苗接种率已经超过了邻国日本，尽管日本政府正赶在7月份奥运会开幕前加紧为国民接种疫苗。虽然日韩两国都是在今年4月才开始疫苗接种工作，但近日韩国每100人累计接种数已跃升至30多剂，而日本仅略高于20剂。

China, which also suffered initial delays, has administered more than 900m doses to its population of 1.4bn.

中国的疫苗接种计划最初也出现拖延，现在已为14亿人口接种了逾9亿剂疫苗。

Jeong Eun-kyeoung, head of the Korea Disease Control and Prevention Agency, said 80m doses would arrive in South Korea in the third quarter of the year, including 10m doses in July.

韩国疾病管理厅(Korea Disease Control and Prevention Agency)厅长郑银敬(Jeong Eun-kyeyoung)表示，今年第三季度将有8000万剂疫苗抵达韩国，其中1000万剂将在7月份抵达。

“There is hope for returning to ordinary life . . . But we cannot stop the community spread of the virus with the current vaccination rate,” Jeong said.

郑银敬说：“恢复正常生活是有希望的……但以目前的疫苗接种率，我们无法阻止病毒的社区传播。”

To encourage vaccination, South Korea is introducing incentives such as allowing vaccinated people to go maskless outdoors and to be exempt from restrictions of gatherings of more than four people. Inoculation locations are also being expanded to companies with their own medical facilities.

为了鼓励接种疫苗，韩国正在推出一些激励措施，比如允许接种了疫苗的人不戴口罩外出，以及举行四人以上的集会。接种点也在增加，拥有自己医疗设施的公司可以设接种点。

Local confidence has been buoyed by a series of commercial deals between South Korean biopharmaceutical groups and leading foreign vaccine developers.

韩国生物制药集团与外国领先疫苗开发商之间的一系列商业交易，提振了韩国人的信心。

SK Bioscience is contracted to produce AstraZeneca jabs for both domestic use and export. It also signed a licence agreement with Novavax to produce 40m doses for South Korea as well as a contract manufacturing deal for global supply.

SK生物科学(SK Bioscience)已签约为阿斯利康生产疫苗，供韩国国内使用和出口。该公司还与诺瓦瓦克斯(Novavax)签署了一项许可协议，为韩国生产4000万剂疫苗，还签署了一份合同制造(contract manufacturing)协议，生产供应外国的疫苗。

Samsung Biologics, the country’s biggest pharmaceutical contract manufacturer, plans to start Moderna vaccine production in the second half of the year for South Korea and the global market, excluding the US. Another biotech, GL Rapha, will produce doses of Russia’s Sputnik V jab for global use.

韩国最大的药品合同制造商三星生物制剂(Samsung Biologics)计划于今年下半年开始为韩国和除美国以外的全球市场生产莫德纳(Moderna)疫苗。另一家生物技术公司GL Rapha将生产供应外国的俄罗斯“卫星-V”(Sputnik V)疫苗。

本文6月18日发布于FT中文网，英文原题为 South Korea vaccination surge adds impetus to Asia push lBXz1xsjPiqsqZy0h/1mZW/ikkAl0vQFdYNvkjl1EU5j5/OfkxwY+whtZWNikPJC